Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

The Role and Application of Fibroblast Activating Protein

Author(s): Xiao-lou Zhang, Wang Xiao, Jian-ping Qian, Wan-jun Yang, Hao Xu, Xing-da Xu and Guo-wei Zhang*

Volume 24, Issue 9, 2024

Published on: 26 September, 2023

Page: [1097 - 1110] Pages: 14

DOI: 10.2174/1566524023666230530095305

Price: $65

Abstract

Fibroblast activation protein-α (FAP), a type-II transmembrane serine protease, is rarely expressed in normal tissues but highly abundant in pathological diseases, including fibrosis, arthritis, and cancer. Ever since its discovery, we have deciphered its structure and biological properties and continue to investigate its roles in various diseases while attempting to utilize it for targeted therapy. To date, no significant breakthroughs have been made in terms of efficacy. However, in recent years, several practical applications in the realm of imaging diagnosis have been discovered. Given its unique expression in a diverse array of pathological tissues, the fundamental biological characteristics of FAP render it a crucial target for disease diagnosis and immunotherapy. To obtain a more comprehensive understanding of the research progress of FAP, its biological characteristics, involvement in diseases, and recent targeted application research have been reviewed. Moreover, we explored its development trend in the direction of clinical diagnoses and treatment.

« Previous Next »
[1]
Rettig WJ, Chesa PG, Beresford HR, et al. Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. Cancer Res 1986; 46(12 Pt 1): 6406-12.
[PMID: 2877731]
[2]
Monsky WL, Lin CY, Aoyama A, et al. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res 1994; 54(21): 5702-10.
[PMID: 7923219]
[3]
Aoyama A, Chen WTA. 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci 1990; 87(21): 8296-300.
[http://dx.doi.org/10.1073/pnas.87.21.8296] [PMID: 2172980]
[4]
Goldstein LA, Ghersi G, Piñeiro-Sánchez ML, et al. Molecular cloning of seprase: A serine integral membrane protease from human melanoma. Biochim Biophys Acta Mol Basis Dis 1997; 1361(1): 11-9.
[http://dx.doi.org/10.1016/S0925-4439(97)00032-X] [PMID: 9247085]
[5]
Rettig WJ, Garin-Chesa P, Healey JH, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 1993; 53(14): 3327-35.
[PMID: 8391923]
[6]
Iwasa S, Okada K, Chen WT, et al. ‘Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer’. Cancer Lett 2005; 227(2): 229-36.
[http://dx.doi.org/10.1016/j.canlet.2004.06.030] [PMID: 16196122]
[7]
Kelly T, Kechelava S, Rozypal TL, West KW, Korourian S. Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. Mod Pathol 1998; 11(9): 855-63.
[PMID: 9758365]
[8]
Mori Y, Kono K, Matsumoto Y, et al. The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma. Oncology 2004; 67(5-6): 411-9.
[http://dx.doi.org/10.1159/000082926] [PMID: 15713998]
[9]
Lo A, Li CP, Buza EL, et al. Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. JCI Insight 2017; 2(19): e92232.
[http://dx.doi.org/10.1172/jci.insight.92232] [PMID: 28978805]
[10]
Arnold JN, Magiera L, Kraman M, Fearon DT. Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1. Cancer Immunol Res 2014; 2(2): 121-6.
[http://dx.doi.org/10.1158/2326-6066.CIR-13-0150] [PMID: 24778275]
[11]
Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006; 107(4): 1397-404.
[http://dx.doi.org/10.1182/blood-2005-08-3452] [PMID: 16223769]
[12]
Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl 2014; 8(5-6): 454-63.
[http://dx.doi.org/10.1002/prca.201300095] [PMID: 24470260]
[13]
Christiansen VJ, Jackson KW, Lee KN, Downs TD, McKee PA. Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. Neoplasia 2013; 15(4): 348-58.
[http://dx.doi.org/10.1593/neo.121850] [PMID: 23555181]
[14]
Kelly T, Huang Y, Simms AE, Mazur A. Fibroblast activation protein-α: A key modulator of the microenvironment in multiple pathologies. Int Rev Cell Mol Biol 2012; 297: 83-116.
[http://dx.doi.org/10.1016/B978-0-12-394308-8.00003-0] [PMID: 22608558]
[15]
Aertgeerts K, Levin I, Shi L, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem 2005; 280(20): 19441-4.
[http://dx.doi.org/10.1074/jbc.C500092200] [PMID: 15809306]
[16]
Mathew S, Scanlan MJ, Mohan Raj BK, et al. The gene for fibroblast activation protein α (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics 1995; 25(1): 335-7.
[http://dx.doi.org/10.1016/0888-7543(95)80157-H] [PMID: 7774951]
[17]
Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 2002; 62(16): 4767-72.
[PMID: 12183436]
[18]
Niedermeyer J, Scanlan MJ, Garin-Chesa P, et al. Mouse fibroblast activation protein: Molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer 1997; 71(3): 383-9.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19970502)71:3<383:AID-IJC14>3.0.CO;2-H] [PMID: 9139873]
[19]
Cheng JD, Valianou M, Cheng JD. Identification and characterization of the promoter of fibroblast activation protein. Front Biosci 2010; E2(3): 1154-63.
[http://dx.doi.org/10.2741/e175] [PMID: 20515787]
[20]
Rosenblum JS, Kozarich JW. Prolyl peptidases: A serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003; 7(4): 496-504.
[http://dx.doi.org/10.1016/S1367-5931(03)00084-X] [PMID: 12941425]
[21]
Ghersi G, Dong H, Goldstein LA, et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem 2002; 277(32): 29231-41.
[http://dx.doi.org/10.1074/jbc.M202770200] [PMID: 12023964]
[22]
Piñeiro-Sánchez ML, Goldstein LA, Dodt J, et al. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem 1997; 272(12): 7595-601.
[http://dx.doi.org/10.1074/jbc.272.12.7595] [PMID: 9065413]
[23]
Sun S, Albright CF, Fish BH, et al. Expression, purification, and kinetic characterization of full-length human fibroblast activation protein. Protein Expr Purif 2002; 24(2): 274-81.
[http://dx.doi.org/10.1006/prep.2001.1572] [PMID: 11858723]
[24]
Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999; 274(51): 36505-12.
[http://dx.doi.org/10.1074/jbc.274.51.36505] [PMID: 10593948]
[25]
Tillmanns J, Hoffmann D, Habbaba Y, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol 2015; 87: 194-203.
[http://dx.doi.org/10.1016/j.yjmcc.2015.08.016] [PMID: 26319660]
[26]
Cheng JD, Valianou M, Canutescu AA, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther 2005; 4(3): 351-60.
[http://dx.doi.org/10.1158/1535-7163.MCT-04-0269] [PMID: 15767544]
[27]
Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 2003; 22(2/3): 259-69.
[http://dx.doi.org/10.1023/A:1023055600919] [PMID: 12785000]
[28]
O’Brien P, O’Connor BF. Seprase: An overview of an important matrix serine protease. Biochim Biophys Acta Proteins Proteomics 2008; 1784(9): 1130-45.
[http://dx.doi.org/10.1016/j.bbapap.2008.01.006] [PMID: 18262497]
[29]
Ramirez-Montagut T, Blachere NE, Sviderskaya EV, et al. FAPα, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene 2004; 23(32): 5435-46.
[http://dx.doi.org/10.1038/sj.onc.1207730] [PMID: 15133496]
[30]
Yang W, Han W, Ye S, et al. Fibroblast activation protein-α promotes ovarian cancer cell proliferation and invasion via extracellular and intracellular signaling mechanisms. Exp Mol Pathol 2013; 95(1): 105-10.
[http://dx.doi.org/10.1016/j.yexmp.2013.06.007] [PMID: 23778090]
[31]
Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011; 11(1): 245.
[http://dx.doi.org/10.1186/1471-2407-11-245] [PMID: 21668992]
[32]
Wang XM, Yu DMT, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 2005; 42(4): 935-45.
[http://dx.doi.org/10.1002/hep.20853] [PMID: 16175601]
[33]
Brown DD, Wang Z, Furlow JD, et al. The thyroid hormone-induced tail resorption program during Xenopus laevis metamorphosis. Proc Natl Acad Sci 1996; 93(5): 1924-9.
[http://dx.doi.org/10.1073/pnas.93.5.1924] [PMID: 8700860]
[34]
Roberts EW, Deonarine A, Jones JO, et al. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med 2013; 210(6): 1137-51.
[http://dx.doi.org/10.1084/jem.20122344] [PMID: 23712428]
[35]
Liu J, Huang C, Peng C, et al. Stromal fibroblast activation protein alpha promotes gastric cancer progression via epithelial-mesenchymal transition through Wnt/β-catenin pathway. BMC Cancer 2018; 18(1): 1099.
[http://dx.doi.org/10.1186/s12885-018-5035-9] [PMID: 30419872]
[36]
Tsujimoto H, Nishizuka S, Redpath JL, Stanbridge EJ. Differential gene expression in tumorigenic and nontumorigenic HeLa normal human fibroblast hybrid cells. Mol Carcinog 1999; 26(4): 298-304.
[http://dx.doi.org/10.1002/(SICI)1098-2744(199912)26:4<298:AID-MC8>3.0.CO;2-M] [PMID: 10569806]
[37]
Fischer E, Chaitanya K, Wüest T, et al. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res 2012; 18(22): 6208-18.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-0644] [PMID: 22992515]
[38]
Jones B, Adams S, Miller GT, Jesson MI, Watanabe T, Wallner BP. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood 2003; 102(5): 1641-8.
[http://dx.doi.org/10.1182/blood-2003-01-0208] [PMID: 12738665]
[39]
Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res 2004; 64(15): 5471-80.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-0447] [PMID: 15289357]
[40]
Coutts SJ, Kelly TA, Snow RJ, et al. Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. J Med Chem 1996; 39(10): 2087-94.
[http://dx.doi.org/10.1021/jm950732f] [PMID: 8642568]
[41]
Lai D, Ma L, Wang F. Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells. Int J Oncol 2012; 41(2): 541-50.
[http://dx.doi.org/10.3892/ijo.2012.1475] [PMID: 22614695]
[42]
Wu G, Xie B, Lu C, Chen C, Zhou J, Deng Z. microRNA-30a attenuates TGF - β 1–induced activation of pulmonary fibroblast cell by targeting FAP-α. J Cell Mol Med 2020; 24(6): 3745-50.
[http://dx.doi.org/10.1111/jcmm.15020] [PMID: 31991519]
[43]
Dobie R, West CC, Henderson BEP, et al. Deciphering mesenchymal drivers of human dupuytren’s disease at single-cell level. J Invest Dermatol 2022; 142(1): 114-123.e8.
[http://dx.doi.org/10.1016/j.jid.2021.05.030] [PMID: 34274346]
[44]
Niedermeyer J, Kriz M, Hilberg F, et al. Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol 2000; 20(3): 1089-94.
[http://dx.doi.org/10.1128/MCB.20.3.1089-1094.2000] [PMID: 10629066]
[45]
Acharya PS, Zukas A, Chandan V, Katzenstein ALA, Puré E. Fibroblast activation protein: A serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol 2006; 37(3): 352-60.
[http://dx.doi.org/10.1016/j.humpath.2005.11.020] [PMID: 16613331]
[46]
Wenlong L, Leilei Y, Wei F, et al. Luciferase expression is driven by the promoter of fibroblast activation protein-α in murine pulmonary fibrosis. Biotechnol Lett 2015; 37(9): 1757-63.
[http://dx.doi.org/10.1007/s10529-015-1855-8] [PMID: 25994578]
[47]
Fan MH, Zhu Q, Li HH, et al. Fibroblast Activation Protein (FAP) accelerates collagen degradation and clearance from lungs in mice. J Biol Chem 2016; 291(15): 8070-89.
[http://dx.doi.org/10.1074/jbc.M115.701433] [PMID: 26663085]
[48]
Ahn JY, Kim MH, Lim MJ, et al. The inhibitory effect of ginsan on TGF-β mediated fibrotic process. J Cell Physiol 2011; 226(5): 1241-7.
[http://dx.doi.org/10.1002/jcp.22452] [PMID: 20945375]
[49]
Egger C, Cannet C, Gérard C, et al. Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol 2017; 809: 64-72.
[http://dx.doi.org/10.1016/j.ejphar.2017.05.022] [PMID: 28506908]
[50]
Kimura T, Monslow J, Klampatsa A, et al. Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-β and chronic bleomycin-induced fibrosis. Am J Physiol Lung Cell Mol Physiol 2019; 317(2): L271-82.
[http://dx.doi.org/10.1152/ajplung.00071.2019] [PMID: 31188013]
[51]
Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999; 29(6): 1768-78.
[http://dx.doi.org/10.1002/hep.510290631] [PMID: 10347120]
[52]
Levy MT, McCaughan GW, Marinos G, Gorrell MD. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver 2002; 22(2): 93-101.
[http://dx.doi.org/10.1034/j.1600-0676.2002.01503.x] [PMID: 12028401]
[53]
Keane FM, Yao TW, Seelk S, et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio 2014; 4(1): 43-54.
[http://dx.doi.org/10.1016/j.fob.2013.12.001] [PMID: 24371721]
[54]
Uitte de Willige S, Malfliet JJMC, Janssen HLA, Leebeek FWG, Rijken DC. Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis. J Thromb Haemost 2013; 11(11): 2029-36.
[http://dx.doi.org/10.1111/jth.12396] [PMID: 24034420]
[55]
Uitte de Willige S, Keane FM, Bowen DG, et al. Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. PLoS One 2017; 12(6): e0178987.
[http://dx.doi.org/10.1371/journal.pone.0178987] [PMID: 28582421]
[56]
Williams KH, Viera de Ribeiro AJ, Prakoso E, et al. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Res Clin Pract 2015; 108(3): 466-72.
[http://dx.doi.org/10.1016/j.diabres.2015.02.024] [PMID: 25836944]
[57]
Yang AT, Kim YO, Yan XZ, et al. Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis. Cell Mol Gastroenterol Hepatol 2023; 15(4): 841-67.
[http://dx.doi.org/10.1016/j.jcmgh.2022.12.005] [PMID: 36521660]
[58]
Rovedatti L, Di Sabatino A, Knowles CH, et al. Fibroblast activation protein expression in Crohn's disease strictures. Inflamm Bowel Dis 2011; 17(5): 1251-3.
[http://dx.doi.org/10.1002/ibd.21446] [PMID: 20806341]
[59]
Truffi M, Sorrentino L, Monieri M, et al. Inhibition of fibroblast activation protein restores a balanced extracellular matrix and reduces fibrosis in crohn’s disease strictures ex vivo. Inflamm Bowel Dis 2018; 24(2): 332-45.
[http://dx.doi.org/10.1093/ibd/izx008] [PMID: 29361086]
[60]
Dienus K, Bayat A, Gilmore BF, Seifert O. Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: Implications for development of a novel treatment option. Arch Dermatol Res 2010; 302(10): 725-31.
[http://dx.doi.org/10.1007/s00403-010-1084-x] [PMID: 20872224]
[61]
Milner JM, Kevorkian L, Young DA, et al. Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis. Arthritis Res Ther 2006; 8(1): R23.
[http://dx.doi.org/10.1186/ar1877] [PMID: 16507127]
[62]
Bauer S, Jendro MC, Wadle A, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006; 8(6): R171.
[http://dx.doi.org/10.1186/ar2080] [PMID: 17105646]
[63]
Laverman P, van der Geest T, Terry SYA, et al. Immuno-PET and Immuno-SPECT of rheumatoid arthritis with radiolabeled anti–fibroblast activation protein antibody correlates with severity of arthritis. J Nucl Med 2015; 56(5): 778-83.
[http://dx.doi.org/10.2967/jnumed.114.152959] [PMID: 25858044]
[64]
Ospelt C, Mertens JC, Jüngel A, et al. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2010; 62(5): 1224-35.
[http://dx.doi.org/10.1002/art.27395] [PMID: 20155839]
[65]
Wäldele S, Koers-Wunrau C, Beckmann D, et al. Deficiency of fibroblast activation protein alpha ameliorates cartilage destruction in inflammatory destructive arthritis. Arthritis Res Ther 2015; 17(1): 12.
[http://dx.doi.org/10.1186/s13075-015-0524-6] [PMID: 25600705]
[66]
Croft AP, Campos J, Jansen K, et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 2019; 570(7760): 246-51.
[http://dx.doi.org/10.1038/s41586-019-1263-7] [PMID: 31142839]
[67]
Uitte de Willige S, Malfliet JJMC, Deckers JW, Dippel DWJ, Leebeek FWG, Rijken DC. Plasma levels of soluble fibroblast activation protein in arterial thrombosis; determinants and cleavage of its substrate alpha-2-antiplasmin. Int J Cardiol 2015; 178: 105-10.
[http://dx.doi.org/10.1016/j.ijcard.2014.10.091] [PMID: 25464232]
[68]
Brokopp CE, Schoenauer R, Richards P, et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur Heart J 2011; 32(21): 2713-22.
[http://dx.doi.org/10.1093/eurheartj/ehq519] [PMID: 21292680]
[69]
Stein S, Weber J, Nusser-Stein S, et al. Deletion of fibroblast activation protein provides atheroprotection. Cardiovasc Res 2021; 117(4): 1060-9.
[http://dx.doi.org/10.1093/cvr/cvaa142] [PMID: 32402085]
[70]
Tillmanns J, Fraccarollo D, Galuppo P, Wollert KC, Bauersachs J. Changes in concentrations of circulating fibroblast activation protein alpha are associated with myocardial damage in patients with acute ST-elevation MI. Int J Cardiol 2017; 232: 155-9.
[http://dx.doi.org/10.1016/j.ijcard.2017.01.037] [PMID: 28082091]
[71]
Blomberg R, Beiting DP, Wabitsch M, Puré E. Fibroblast activation protein restrains adipogenic differentiation and regulates matrix-mediated mTOR signaling. Matrix Biol 2019; 83: 60-76.
[http://dx.doi.org/10.1016/j.matbio.2019.07.007] [PMID: 31325484]
[72]
Zhen EY, Jin Z, Ackermann BL, Thomas MK, Gutierrez JA. Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. Biochem J 2016; 473(5): 605-14.
[http://dx.doi.org/10.1042/BJ20151085] [PMID: 26635356]
[73]
Sánchez-Garrido MA, Habegger KM, Clemmensen C, et al. Fibroblast activation protein (FAP) as a novel metabolic target. Mol Metab 2016; 5(10): 1015-24.
[http://dx.doi.org/10.1016/j.molmet.2016.07.003] [PMID: 27689014]
[74]
Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci 1990; 87(18): 7235-9.
[http://dx.doi.org/10.1073/pnas.87.18.7235] [PMID: 2402505]
[75]
Shi M, Yu DH, Chen Y, et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol 2012; 18(8): 840-6.
[http://dx.doi.org/10.3748/wjg.v18.i8.840] [PMID: 22371645]
[76]
Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 2008; 37(2): 154-8.
[http://dx.doi.org/10.1097/MPA.0b013e31816618ce] [PMID: 18665076]
[77]
Kawase T, Yasui Y, Nishina S, et al. Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma. BMC Gastroenterol 2015; 15(1): 109.
[http://dx.doi.org/10.1186/s12876-015-0340-0] [PMID: 26330349]
[78]
Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330(6005): 827-30.
[http://dx.doi.org/10.1126/science.1195300] [PMID: 21051638]
[79]
Lo A, Wang LCS, Scholler J, et al. Tumor-promoting desmoplasia is disrupted by depleting fap-expressing stromal cells. Cancer Res 2015; 75(14): 2800-10.
[http://dx.doi.org/10.1158/0008-5472.CAN-14-3041] [PMID: 25979873]
[80]
Wang RF, Zhang LH, Shan LH, et al. Effects of the fibroblast activation protein on the invasion and migration of gastric cancer. Exp Mol Pathol 2013; 95(3): 350-6.
[http://dx.doi.org/10.1016/j.yexmp.2013.10.008] [PMID: 24422232]
[81]
Dong R, Guo J, Zhang Z, Zhou Y, Hua Y. Polyphyllin I inhibits gastric cancer cell proliferation by downregulating the expression of fibroblast activation protein alpha (FAP) and hepatocyte growth factor (HGF) in cancer-associated fibroblasts. Biochem Biophys Res Commun 2018; 497(4): 1129-34.
[http://dx.doi.org/10.1016/j.bbrc.2018.02.193] [PMID: 29499193]
[82]
Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007; 13(6): 1736-41.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-1746] [PMID: 17363526]
[83]
Solano-Iturri JD, Beitia M, Errarte P, et al. Altered expression of fibroblast activation protein-α (FAP) in colorectal adenoma-carcinoma sequence and in lymph node and liver metastases. Aging (Albany NY) 2020; 12(11): 10337-58.
[http://dx.doi.org/10.18632/aging.103261] [PMID: 32428869]
[84]
Yuan Z, Hu H, Zhu Y, et al. Colorectal cancer cell intrinsic fibroblast activation protein alpha binds to Enolase1 and activates NF-xB pathway to promote metastasis. Cell Death Dis 2021; 12(6): 543.
[http://dx.doi.org/10.1038/s41419-021-03823-4] [PMID: 34035230]
[85]
Saigusa S, Toiyama Y, Tanaka K, et al. Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. Int J Oncol 2011; 38(3): 655-63.
[http://dx.doi.org/10.3892/ijo.2011.906] [PMID: 21240461]
[86]
Jia J, Martin TA, Ye L, Jiang WG. FAP-α (Fibroblast activation protein-α) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biol 2014; 15(1): 16.
[http://dx.doi.org/10.1186/1471-2121-15-16] [PMID: 24885257]
[87]
Goodman JD, Rozypal TL, Kelly T. Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis 2003; 20(5): 459-70.
[http://dx.doi.org/10.1023/A:1025493605850] [PMID: 14524536]
[88]
Park CK, Jung WH, Koo JS. Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. Breast Cancer Res Treat 2016; 159(1): 55-69.
[http://dx.doi.org/10.1007/s10549-016-3929-2] [PMID: 27469595]
[89]
Ariga N, Sato E, Ohuchi N, Nagura H, Ohtani H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 2001; 95(1): 67-72.
[http://dx.doi.org/10.1002/1097-0215(20010120)95:1<67:AID-IJC1012>3.0.CO;2-U] [PMID: 11241314]
[90]
Huang M, Fu M, Wang J, et al. TGF-β1-activated cancer-associated fibroblasts promote breast cancer invasion, metastasis and epithelial-mesenchymal transition by autophagy or overexpression of FAP-α. Biochem Pharmacol 2021; 188: 114527.
[http://dx.doi.org/10.1016/j.bcp.2021.114527] [PMID: 33741330]
[91]
Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res 2004; 64(8): 2712-6.
[http://dx.doi.org/10.1158/0008-5472.CAN-03-3184] [PMID: 15087384]
[92]
Huber MA, Schubert RD, Peter RU, et al. Fibroblast activation protein: Differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol 2003; 120(2): 182-8.
[http://dx.doi.org/10.1046/j.1523-1747.2003.12035.x] [PMID: 12542520]
[93]
Seifert O, Rosdahl I, Gilmore BF, Seifert O. Ultraviolet exposure of melanoma cells induces fibroblast activation protein-α in fibroblasts: Implications for melanoma invasion. Int J Oncol 2011; 39(1): 193-202.
[http://dx.doi.org/10.3892/ijo.2011.1002] [PMID: 21491083]
[94]
Wäster P, Orfanidis K, Eriksson I, Rosdahl I, Seifert O, Öllinger K. UV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins–TGF-β1–FAP-α. Br J Cancer 2017; 117(4): 535-44.
[http://dx.doi.org/10.1038/bjc.2017.182] [PMID: 28697174]
[95]
Chen X, Liu X, Wang L, et al. Expression of fibroblast activation protein in lung cancer and its correlation with tumor glucose metabolism and histopathology. Eur J Nucl Med Mol Imaging 2022; 49(8): 2938-48.
[http://dx.doi.org/10.1007/s00259-022-05754-4] [PMID: 35254482]
[96]
Moreno-Ruiz P, Corvigno S, te Grootenhuis NC, et al. Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation. Lung Cancer 2021; 155: 10-9.
[http://dx.doi.org/10.1016/j.lungcan.2021.02.028] [PMID: 33706022]
[97]
Jia J, Martin T, Ye L, et al. Fibroblast activation protein-α promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways. Int J Mol Med 2017; 41(1): 275-83.
[http://dx.doi.org/10.3892/ijmm.2017.3224] [PMID: 29115573]
[98]
Pennisi A, Li X, Ling W, et al. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. Br J Haematol 2009; 145(6): 775-87.
[http://dx.doi.org/10.1111/j.1365-2141.2009.07696.x] [PMID: 19388929]
[99]
Wei H, Xu Y, Wang Y, et al. Identification of fibroblast activation protein as an osteogenic suppressor and anti-osteoporosis drug target. Cell Rep 2020; 33(2): 108252.
[http://dx.doi.org/10.1016/j.celrep.2020.108252] [PMID: 33053358]
[100]
Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J Jr, Yaccoby S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol 2006; 133(1): 83-92.
[http://dx.doi.org/10.1111/j.1365-2141.2006.05976.x] [PMID: 16512833]
[101]
Bae S, Park CW, Son HK, et al. Fibroblast activation protein α identifies mesenchymal stromal cells from human bone marrow. Br J Haematol 2008; 142(5): 827-30.
[http://dx.doi.org/10.1111/j.1365-2141.2008.07241.x] [PMID: 18510677]
[102]
Zeng C, Wen M, Liu X. Fibroblast activation protein in osteosarcoma cells promotes angiogenesis via AKT and ERK signaling pathways. Oncol Lett 2018; 15(4): 6029-35.
[http://dx.doi.org/10.3892/ol.2018.8027] [PMID: 29552230]
[103]
da Silva AC, Jammal MP, Etchebehere RM, Murta EFC, Nomelini RS. Role of alpha-smooth muscle actin and fibroblast activation protein alpha in ovarian neoplasms. Gynecol Obstet Invest 2018; 83(4): 381-7.
[http://dx.doi.org/10.1159/000488088] [PMID: 29621774]
[104]
Li M, Cheng X, Rong R, Gao Y, Tang X, Chen Y. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer. BMC Cancer 2020; 20(1): 1032.
[http://dx.doi.org/10.1186/s12885-020-07541-6] [PMID: 33109151]
[105]
Yang L, Ma L, Lai D. Over-expression of fibroblast activation protein alpha increases tumor growth in xenografts of ovarian cancer cells. Acta Biochim Biophys Sin 2013; 45(11): 928-37.
[http://dx.doi.org/10.1093/abbs/gmt095] [PMID: 24028972]
[106]
Balaziova E, Vymola P, Hrabal P, et al. Fibroblast activation protein expressing mesenchymal cells promote glioblastoma angiogenesis. Cancers 2021; 13(13): 3304.
[http://dx.doi.org/10.3390/cancers13133304] [PMID: 34282761]
[107]
Krepela E, Vanickova Z, Hrabal P, et al. Regulation of fibroblast activation protein by transforming growth factor beta-1 in glioblastoma microenvironment. Int J Mol Sci 2021; 22(3): 1046.
[http://dx.doi.org/10.3390/ijms22031046] [PMID: 33494271]
[108]
Zeng H, Li H, Zhao Y, Chen L, Ma X. Transcripto-based network analysis reveals a model of gene activation in tongue squamous cell carcinomas. Head Neck 2019; 41(12): 4098-110.
[http://dx.doi.org/10.1002/hed.25952] [PMID: 31589000]
[109]
Wu Q, Zhao M, Huang G, et al. Fibroblast Activation Protein (FAP) overexpression induces epithelial–mesenchymal transition (EMT) in oral squamous cell carcinoma by down-regulating dipeptidyl peptidase 9 (DPP9). OncoTargets Ther 2020; 13: 2599-611.
[http://dx.doi.org/10.2147/OTT.S243417] [PMID: 32273729]
[110]
Park YJ, Kim EK, Bae JY, Moon S, Kim J. Human telomerase reverse transcriptase (hTERT) promotes cancer invasion by modulating cathepsin D via early growth response (EGR)-1. Cancer Lett 2016; 370(2): 222-31.
[http://dx.doi.org/10.1016/j.canlet.2015.10.021] [PMID: 26519755]
[111]
Linz C, Brands RC, Kertels O, et al. Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [18F]FDG PET/CT and MRI. Eur J Nucl Med Mol Imaging 2021; 48(12): 3951-60.
[http://dx.doi.org/10.1007/s00259-021-05422-z] [PMID: 34050405]
[112]
Higashino N, Koma Y, Hosono M, et al. Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma. Lab Invest 2019; 99(6): 777-92.
[http://dx.doi.org/10.1038/s41374-018-0185-6] [PMID: 30683902]
[113]
Sato H, Noma K, Ohara T, et al. Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment. Sci Rep 2022; 12(1): 20152.
[http://dx.doi.org/10.1038/s41598-022-24313-3] [PMID: 36418422]
[114]
Li F, Wu X, Sun Z, Cai P, Wu L, Li D. Fibroblast activation protein-α expressing fibroblasts promote lymph node metastasis in esophageal squamous cell carcinoma. OncoTargets Ther 2020; 13: 8141-8.
[http://dx.doi.org/10.2147/OTT.S257529] [PMID: 32884296]
[115]
Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. J Nucl Med 2019; 60(6): 801-5.
[http://dx.doi.org/10.2967/jnumed.119.227967] [PMID: 30954939]
[116]
Hu X, Zhou T, Ren J, et al. Response prediction using (18)F-FAPI-04 PET/CT in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy. J Nucl Med 2023; 64(4): 625-31.
[http://dx.doi.org/10.2967/jnumed.122.264638] [PMID: 36229183]
[117]
Altmann A, Kratochwil C, Giesel F, Haberkorn U. Ligand engineering for theranostic applications. Curr Opin Chem Biol 2021; 63: 145-51.
[http://dx.doi.org/10.1016/j.cbpa.2021.04.006] [PMID: 34004409]
[118]
Giesel FL, Kratochwil C, Lindner T, et al. 68Ga-FAPI PET/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med 2019; 60(3): 386-92.
[http://dx.doi.org/10.2967/jnumed.118.215913] [PMID: 30072500]
[119]
Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med 2021; 62(2): 160-7.
[http://dx.doi.org/10.2967/jnumed.120.244806] [PMID: 33127618]
[120]
Guo W, Chen H. 68Ga FAPI PET/CT imaging in peritoneal carcinomatosis. Radiology 2020; 297(3): 521.
[http://dx.doi.org/10.1148/radiol.2020202469] [PMID: 33048036]
[121]
Röhrich M, Loktev A, Wefers AK, et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT. Eur J Nucl Med Mol Imaging 2019; 46(12): 2569-80.
[http://dx.doi.org/10.1007/s00259-019-04444-y] [PMID: 31388723]
[122]
Luo Y, Pan Q, Yang H, Peng L, Zhang W, Li F. Fibroblast activation protein–targeted PET/CT with 68 Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT. J Nucl Med 2021; 62(2): 266-71.
[http://dx.doi.org/10.2967/jnumed.120.244723] [PMID: 32513902]
[123]
Heckmann MB, Reinhardt F, Finke D, et al. relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging 2020; 13(9): e010628.
[http://dx.doi.org/10.1161/CIRCIMAGING.120.010628] [PMID: 32912030]
[124]
Diekmann J, Koenig T, Zwadlo C, et al. Molecular imaging identifies fibroblast activation beyond the infarct region after acute myocardial infarction. J Am Coll Cardiol 2021; 77(14): 1835-7.
[http://dx.doi.org/10.1016/j.jacc.2021.02.019] [PMID: 33832609]
[125]
Langer LBN, Hess A, Korkmaz Z, et al. Molecular imaging of fibroblast activation protein after myocardial infarction using the novel radiotracer [68Ga]MHLL1. Theranostics 2021; 11(16): 7755-66.
[http://dx.doi.org/10.7150/thno.51419] [PMID: 34335962]
[126]
Schmidkonz C, Rauber S, Atzinger A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis 2020; 79(11): 1485-91.
[http://dx.doi.org/10.1136/annrheumdis-2020-217408] [PMID: 32719042]
[127]
Wegrzyniak O, Rosestedt M, Eriksson O. Recent progress in the molecular imaging of nonalcoholic fatty liver disease. Int J Mol Sci 2021; 22(14): 7348.
[http://dx.doi.org/10.3390/ijms22147348] [PMID: 34298967]
[128]
Zhang X, Chen D, Babich JW, Green SJE, Deng XH, Rodeo SA. In vivo imaging of fibroblast activity using a 68Ga-labeled fibroblast activation protein alpha (FAP-α) inhibitor. J Bone Joint Surg Am 2021; 103(10): e40.
[http://dx.doi.org/10.2106/JBJS.20.00831] [PMID: 33587512]
[129]
Lindner T, Altmann A, Krämer S, et al. Design and development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188 Re Therapy. J Nucl Med 2020; 61(10): 1507-13.
[http://dx.doi.org/10.2967/jnumed.119.239731] [PMID: 32169911]
[130]
Toms J, Kogler J, Maschauer S, et al. Targeting fibroblast activation protein: Radiosynthesis and preclinical evaluation of an 18F-Labeled FAP inhibitor. J Nucl Med 2020; 61(12): 1806-13.
[http://dx.doi.org/10.2967/jnumed.120.242958] [PMID: 32332144]
[131]
Roy J, Hettiarachchi SU, Kaake M, Mukkamala R, Low PS. Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents. Theranostics 2020; 10(13): 5778-89.
[http://dx.doi.org/10.7150/thno.41409] [PMID: 32483418]
[132]
Hintz HM, Gallant JP, Vander Griend DJ, Coleman IM, Nelson PS, LeBeau AM. Imaging fibroblast activation protein alpha improves diagnosis of metastatic prostate cancer with positron emission tomography. Clin Cancer Res 2020; 26(18): 4882-91.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-1358] [PMID: 32636317]
[133]
Kuyumcu S, Kovan B, Sanli Y, et al. Safety of fibroblast activation protein–targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04. Clin Nucl Med 2021; 46(8): 641-6.
[http://dx.doi.org/10.1097/RLU.0000000000003667] [PMID: 33883494]
[134]
Loktev A, Lindner T, Burger EM, et al. Development of fibroblast activation protein–targeted radiotracers with improved tumor retention. J Nucl Med 2019; 60(10): 1421-9.
[http://dx.doi.org/10.2967/jnumed.118.224469] [PMID: 30850501]
[135]
Lin Y, Ma Z, Li Z, et al. Bioluminescent probe for monitoring endogenous fibroblast activation protein-alpha. Anal Chem 2019; 91(23): 14873-8.
[http://dx.doi.org/10.1021/acs.analchem.9b02117] [PMID: 31670506]
[136]
Zhao XX, Li LL, Zhao Y, et al. In situ self-assembled nanofibers precisely target cancer-associated fibroblasts for improved tumor imaging. Angew Chem Int Ed 2019; 58(43): 15287-94.
[http://dx.doi.org/10.1002/anie.201908185] [PMID: 31402550]
[137]
Fu A, Wang H, Huo T, et al. A novel chemiluminescence probe for sensitive detection of fibroblast activation protein-alpha in vitro and in living systems. Anal Chem 2021; 93(16): 6501-7.
[http://dx.doi.org/10.1021/acs.analchem.1c00413] [PMID: 33866786]
[138]
Gong Q, Shi W, Li L, Wu X, Ma H. Ultrasensitive fluorescent probes reveal an adverse action of dipeptide peptidase iv and fibroblast activation protein during proliferation of cancer cells. Anal Chem 2016; 88(16): 8309-14.
[http://dx.doi.org/10.1021/acs.analchem.6b02231] [PMID: 27444320]
[139]
Li J, Chen K, Liu H, et al. Activatable near-infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha. Bioconjug Chem 2012; 23(8): 1704-11.
[http://dx.doi.org/10.1021/bc300278r] [PMID: 22812530]
[140]
Miao Q, Yeo DC, Wiraja C, et al. Near-infrared fluorescent molecular probe for sensitive imaging of keloid. Angew Chem Int Ed 2018; 57(5): 1256-60.
[http://dx.doi.org/10.1002/anie.201710727] [PMID: 29316083]
[141]
Xing J, Gong Q, Zou R, et al. A novel fibroblast activation protein-targeted near-infrared fluorescent off–on probe for cancer cell detection, in vitro and in vivo imaging. J Mater Chem B Mater Biol Med 2018; 6(10): 1449-51.
[http://dx.doi.org/10.1039/C7TB03303F] [PMID: 32254208]
[142]
Ke MR, Chen SF, Peng XH, et al. A tumor-targeted activatable phthalocyanine-tetrapeptide-doxorubicin conjugate for synergistic chemo-photodynamic therapy. Eur J Med Chem 2017; 127: 200-9.
[http://dx.doi.org/10.1016/j.ejmech.2016.12.056] [PMID: 28063352]
[143]
Wang LCS, Lo A, Scholler J, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2014; 2(2): 154-66.
[http://dx.doi.org/10.1158/2326-6066.CIR-13-0027] [PMID: 24778279]
[144]
Aghajanian H, Kimura T, Rurik JG, et al. Targeting cardiac fibrosis with engineered T cells. Nature 2019; 573(7774): 430-3.
[http://dx.doi.org/10.1038/s41586-019-1546-z] [PMID: 31511695]
[145]
Tran E, Chinnasamy D, Yu Z, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 2013; 210(6): 1125-35.
[http://dx.doi.org/10.1084/jem.20130110] [PMID: 23712432]
[146]
Petrausch U, Schuberth PC, Hagedorn C, et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer 2012; 12(1): 615.
[http://dx.doi.org/10.1186/1471-2407-12-615] [PMID: 23259649]
[147]
Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116(7): 1955-62.
[http://dx.doi.org/10.1172/JCI26532] [PMID: 16794736]
[148]
de Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M, Alemany R. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J Immunother Cancer 2019; 7(1): 19.
[http://dx.doi.org/10.1186/s40425-019-0505-4] [PMID: 30683154]
[149]
Geng F, Bao X, Dong L, et al. Doxorubicin pretreatment enhances FAPα/survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model. OncoImmunology 2020; 9(1): 1747350.
[http://dx.doi.org/10.1080/2162402X.2020.1747350] [PMID: 32363118]
[150]
Fabre M, Ferrer C, Domínguez-Hormaetxe S, et al. OMTX705, a Novel FAP-Targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models. Clin Cancer Res 2020; 26(13): 3420-30.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-2238] [PMID: 32161121]
[151]
Li X, Chen M, Lu W, et al. Targeting FAPα-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis. Cancer Lett 2021; 503: 32-42.
[http://dx.doi.org/10.1016/j.canlet.2021.01.013] [PMID: 33482262]
[152]
Yang Z, Zhang L, Zhu H, et al. Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast. J Cell Mol Med 2021; 25(7): 3511-23.
[http://dx.doi.org/10.1111/jcmm.16434] [PMID: 33713546]
[153]
Dorst DN, van Caam APM, Vitters EL, et al. Fibroblast activation protein targeted photodynamic therapy selectively kills activated skin fibroblasts from systemic sclerosis patients and prevents tissue contraction. Int J Mol Sci 2021; 22(23): 12681.
[http://dx.doi.org/10.3390/ijms222312681] [PMID: 34884484]
[154]
Sun J, Yang D, Cui SH, et al. Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation. Int J Pharm 2019; 559: 48-57.
[http://dx.doi.org/10.1016/j.ijpharm.2019.01.032] [PMID: 30677483]
[155]
Lang J, Zhao X, Qi Y, et al. Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem. ACS Nano 2019; 13(11): 12357-71.
[http://dx.doi.org/10.1021/acsnano.9b04857] [PMID: 31545587]
[156]
Teng C, Zhang B, Yuan Z, et al. Fibroblast activation protein-α-adaptive micelles deliver anti-cancer drugs and reprogram stroma fibrosis. Nanoscale 2020; 12(46): 23756-67.
[http://dx.doi.org/10.1039/D0NR04465B] [PMID: 33231238]
[157]
Kuklik J, Michelfelder S, Schiele F, et al. Development of a bispecific antibody-based platform for retargeting of capsid modified AAV vectors. Int J Mol Sci 2021; 22(15): 8355.
[http://dx.doi.org/10.3390/ijms22158355] [PMID: 34361120]
[158]
Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Oncol Res Treat 2003; 26(1): 44-8.
[http://dx.doi.org/10.1159/000069863] [PMID: 12624517]
[159]
Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003; 9(5): 1639-47.
[PMID: 12738716]
[160]
Plescia J, De Cesco S, Patrascu MB, et al. Integrated synthetic, biophysical, and computational investigations of covalent inhibitors of prolyl oligopeptidase and fibroblast activation protein α. J Med Chem 2019; 62(17): 7874-84.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00642] [PMID: 31393718]
[161]
Watabe T, Liu Y, Kaneda-Nakashima K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-Labeled FAPI-04 in pancreatic cancer xenograft mouse models. J Nucl Med 2020; 61(4): 563-9.
[http://dx.doi.org/10.2967/jnumed.119.233122] [PMID: 31586001]
[162]
Calais J. FAP: The next billion dollar nuclear theranostics target? J Nucl Med 2020; 61(2): 163-5.
[http://dx.doi.org/10.2967/jnumed.119.241232] [PMID: 31924719]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy